Patents by Inventor Olaf MUNDSZINGER
Olaf MUNDSZINGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210386691Abstract: The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.Type: ApplicationFiled: August 30, 2021Publication date: December 16, 2021Inventors: Sascha MANTHEI, Helene REY, Marc FISCHER, Olaf MUNDSZINGER
-
Patent number: 11103467Abstract: A method for treating depression in patients with depression and bipolar disorder who have not responded to antidepressants and to avoid dose dumping upon ingestion of alcohol. The present invention also relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.Type: GrantFiled: June 11, 2019Date of Patent: August 31, 2021Assignee: Develco Pharma Schweiz AGInventors: Sascha Manthei, Helene Rey, Marc Fischer, Olaf Mundszinger
-
Publication number: 20190290600Abstract: A method for treating depression in patients with depression and bipolar disorder who have not responded to antidepressants and to avoid dose dumping upon ingestion of alcohol. The present invention also relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.Type: ApplicationFiled: June 11, 2019Publication date: September 26, 2019Inventors: Sascha MANTHEI, Helene REY, Marc FISCHER, Olaf MUNDSZINGER
-
Patent number: 10335379Abstract: The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.Type: GrantFiled: April 16, 2015Date of Patent: July 2, 2019Assignee: Develco Pharma Schweiz AGInventors: Sascha Andor Manthei, Helene Rey, Marc Fischer, Olaf Mundszinger
-
Patent number: 10105360Abstract: The invention relates to a method of treatment using a solid oral pharmaceutical dosage form comprising an opioid receptor antagonist for use in the treatment of opioid induced constipation comprising the opioid antagonist equivalent to 24 mg of naloxone hydrochloride as twice daily formulation or equivalent to 48 mg of naloxone hydrochloride as once daily formulation, characterized in that the opioid antagonist has a rapid first pass metabolism with a plasma half-life of 2 hours or less in humans within the first 3 hours of oral administration of a solution, wherein the steady state pharmacokinetics result in a constant level of naloxone in the bloodstream, wherein the pharmacokinetics are independent of whether the dosage is administered once or twice daily, wherein the oral dosage form releases the opioid antagonist in a prolonged manner, wherein the in vitro release rate of the opioid antagonist measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 1000 ml 0.Type: GrantFiled: September 2, 2016Date of Patent: October 23, 2018Assignee: DEVELCO PHARMA SCHWEIZ AGInventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
-
Patent number: 10058547Abstract: The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutical acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95 % in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC50/Cmax value of at least 40. In an alternative embodiment, the composition can be a multilayer tablet.Type: GrantFiled: September 2, 2016Date of Patent: August 28, 2018Assignee: Develco Pharma Schweiz AGInventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
-
Publication number: 20170087150Abstract: The invention relates to a method of treatment using a solid oral pharmaceutical dosage form comprising an opioid receptor antagonist for use in the treatment of opioid induced constipation comprising the opioid antagonist equivalent to 24 mg of naloxone hydrochloride as twice daily formulation or equivalent to 48 mg of naloxone hydrochloride as once daily formulation, characterized in that the opioid antagonist has a rapid first pass metabolism with a plasma half-life of 2 hours or less in humans within the first 3 hours of oral administration of a solution, wherein the steady state pharmacokinetics result in a constant level of naloxone in the bloodstream, wherein the pharmacokinetics are independent of whether the dosage is administered once or twice daily, wherein the oral dosage form releases the opioid antagonist in a prolonged manner, wherein the in vitro release rate of the opioid antagonist measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 1000 ml 0.Type: ApplicationFiled: September 2, 2016Publication date: March 30, 2017Inventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
-
Publication number: 20170035707Abstract: The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.Type: ApplicationFiled: April 16, 2015Publication date: February 9, 2017Inventors: Sascha Andor MANTHEI, Helene REY, Marc FISCHER, Olaf MUNDSZINGER
-
Publication number: 20160367550Abstract: The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutical acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95 % in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC50/Cmax value of at least 40. In an alternative embodiment, the composition can be a multilayer tablet.Type: ApplicationFiled: September 2, 2016Publication date: December 22, 2016Inventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Sylvia Jakob, Oliver Rusch
-
Patent number: 9456986Abstract: The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95% in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC50/Cmax value of at least 40. In an alternative embodiment, the composition can be a multilayer tablet.Type: GrantFiled: December 8, 2014Date of Patent: October 4, 2016Assignee: Develco Pharma Schweiz AGInventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Sylvia Jakob, Oliver Rusch
-
Publication number: 20160256451Abstract: The present invention relates to a pharmaceutical composition comprising a ?-receptor antagonist as an active substance, wherein the antagonist is prepared in an extended release formulation. The composition is intended for the treatment of patients with opioid-induced constipation, wherein the dosage of the ?-receptor agonist is independent of the opioid dosage. The preferred dosage of the ?-receptor antagonist of the composition is equivalent to a daily dosage of 20-70 mg naloxone.Type: ApplicationFiled: August 17, 2015Publication date: September 8, 2016Inventors: Helene Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
-
Publication number: 20160256453Abstract: The present invention relates to a pharmaceutical composition comprising an opioid receptor antagonist, or a derivative or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. The composition that is suitable for an administration period of at least twelve-hours for the treatment of severe opioid-induced constipation in patients receiving a daily dosage of opioid equivalent to at least 80 mg of morphine.Type: ApplicationFiled: August 17, 2015Publication date: September 8, 2016Inventors: Helene Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
-
Publication number: 20150238420Abstract: The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95% in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC50/Cmax value of at least 40. In an alternative embodiment, the composition can be a multilayer tablet.Type: ApplicationFiled: December 8, 2014Publication date: August 27, 2015Inventors: Hélène REY, Olaf MUNDSZINGER, Isabelle GOLFIER, Sylvia JAKOB, Oliver RUSCH